ClearPoint Neuro, Inc. (CLPT) Form 10-Q — Oct 28, 2026
ClearPoint Neuro reported Q3 2026 revenue of $12.1 million, up 36% year over year, driven by a 59% jump in neurosurgery navigation and therapy disposables (boosted by the acquired IRRAflow product) and 68% growth in capital equipment and software revenue. The company is not yet profitable: Q3 net loss widened 27% to $7.5 million and nine-month net loss grew 60% to $28.3 million, with gross margin slipping to 58% from 63% and interest expense up 54% on its Oberland Capital notes.
Key figures
- Revenue
- 12075000
- Revenue Yoy
- 36%
- Total Assets
- 112728000
- Cash Position
- 46184000
- Shares Outstanding
- 32054268
- Gross margin q3
- 58% (vs 63% prior year)
- Cumulative deficit
- $245.3 million
- Nine month revenue
- $35.1 million (up 32% from $26.6 million)
- Atm net proceeds q3
- $22.0 million from 1,530,000 shares
- Interest expense q3
- $1.4 million (up 54%)
- Nine month net loss
- $28.3 million (vs $17.8 million prior year)
- Atm remaining capacity
- $27.5 million
- Notes net proceeds to date
- $48.1 million under $105.0 million 2025 NPA
- Notes effective interest rate
- 11.3%
- Operating cash use nine months
- $20.1 million
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.